143 related articles for article (PubMed ID: 24249383)
1. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.
O'Hurley G; Prencipe M; Lundon D; O'Neill A; Boyce S; O'Grady A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2014 Feb; 74(3):306-13. PubMed ID: 24249383
[TBL] [Abstract][Full Text] [Related]
2. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
3. Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.
Haider M; Zhang X; Coleman I; Ericson N; True LD; Lam HM; Brown LG; Ketchanji M; Nghiem B; Lakely B; Coleman R; Montgomery B; Lange PH; Roudier M; Higano CS; Bielas JH; Nelson PS; Vessella RL; Morrissey C
Clin Exp Metastasis; 2016 Mar; 33(3):239-48. PubMed ID: 26667932
[TBL] [Abstract][Full Text] [Related]
4. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum response factor and androgen receptor in prostate cancer.
Prencipe M; O'Neill A; O'Hurley G; Nguyen LK; Fabre A; Bjartell A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2015 Nov; 75(15):1704-17. PubMed ID: 26250344
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
7. Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?
Prencipe M; Madden SF; O'Neill A; O'Hurley G; Culhane A; O'Connor D; Klocker H; Kay EW; Gallagher WM; Watson WR
Prostate; 2013 May; 73(7):743-53. PubMed ID: 23359479
[TBL] [Abstract][Full Text] [Related]
8. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.
Crnalic S; Hörnberg E; Wikström P; Lerner UH; Tieva A; Svensson O; Widmark A; Bergh A
Endocr Relat Cancer; 2010 Dec; 17(4):885-95. PubMed ID: 20688881
[TBL] [Abstract][Full Text] [Related]
9. The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.
Valdez CD; Kunju L; Daignault S; Wojno KJ; Day ML
Prostate; 2013 Dec; 73(16):1776-85. PubMed ID: 24038143
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
12. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
14. Expression of hypoxia inducible factor-1 alpha in matched hormone naive and castrate resistant prostate cancer specimens.
Elsberger B; Lankston L; Orange C; Underwood MA; Edwards J
Cancer Biomark; 2010-2011; 8(1):1-9. PubMed ID: 21896985
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of OCT4 expression in patients with prostate cancer.
Kosaka T; Mikami S; Yoshimine S; Miyazaki Y; Daimon T; Kikuchi E; Miyajima A; Oya M
Hum Pathol; 2016 May; 51():1-8. PubMed ID: 27067776
[TBL] [Abstract][Full Text] [Related]
16. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
18. Metastases of prostate cancer express estrogen receptor-beta.
Lai JS; Brown LG; True LD; Hawley SJ; Etzioni RB; Higano CS; Ho SM; Vessella RL; Corey E
Urology; 2004 Oct; 64(4):814-20. PubMed ID: 15491740
[TBL] [Abstract][Full Text] [Related]
19. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
Fay AP; Albiges L; Bellmunt J
Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
[TBL] [Abstract][Full Text] [Related]
20. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival.
Tait C; Moore D; Hodgson C; Brown M; Morris T; Growcott J; Malone M; Hughes A; Renehan A; Clarke NW; Dive C
BJU Int; 2014 Dec; 114(6b):E70-E73. PubMed ID: 24589330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
